Agilent Technologies, Inc., based in Santa Clara, California, specializes in analytical instruments, software, services, and expertise that help scientists and researchers find solutions across various sectors, including life sciences, diagnostics, and applied markets. For the second quarter of fiscal year 2025, Agilent reported a rise in overall performance.

Revenue for the quarter reached $1.67 billion, marking an increase of 6% year-over-year, or 5.3% on a core basis, when adjusting for currency and acquisitions. The fourth consecutive quarter demonstrating accelerated growth was attributed to increasing demand across all markets and geographic regions. Gross margin was reported at 54.1%, down from 55.1% compared to the prior year, influenced by the impact of tariffs, product mix, and currency fluctuations.

Adjusted diluted earnings per share (EPS) stood at $1.31, a 7% increase from the previous year’s quarter, while GAAP EPS was reported at $0.75, a decline of 29% compared to $1.05 in the same period last year. Total non-GAAP net income was $373 million, contrasted with $356 million in Q2 2024.

Sales breakdown indicated that the Agilent CrossLab Group generated $713 million in revenue, reflecting a 9% growth year-over-year. The Life Sciences and Diagnostics Markets Group increased to $654 million, an 8% rise, while the Applied Markets Group remained relatively flat with $301 million in revenue.

Operating expenses totaled $454 million for the quarter compared to $380 million a year ago. Operating cash flow for the quarter was $221 million, with capital expenditures at $114 million, and Agilent returned $165 million to shareholders through share repurchases and paid out $70 million in dividends.

Looking ahead, Agilent maintained its revenue guidance for the fiscal year 2025 in the range of $6.73 billion to $6.81 billion, indicative of a growth of approximately 3.4% to 4.6%. The guidance for the third quarter is projected between $1.645 billion to $1.675 billion, representing an increase of 4.2% to 6.1% reported and 1.7% to 3.6% on a core basis. Non-GAAP EPS guidance was reaffirmed in the range of $5.54 to $5.61 for the full year. Overall, Agilent’s performance reflects stable growth patterns, underpinned by ongoing market demand despite facing challenges related to tariffs and currency impacts.